Protein clue may predict immunotherapy success in colorectal cancer
NCT ID NCT07508046
First seen Apr 08, 2026 · Last updated May 13, 2026 · Updated 5 times
Summary
This study looked at 100 colorectal cancer patients who had already received immunotherapy. Researchers measured a protein called PHGDH in their tumor samples to see if it was linked to how well the treatment worked and how long patients lived. The goal was to find a new way to predict which patients might benefit most from immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.